Novo Nordisk shares rebound despite disappointing CagriSema trial results

Novo Nordisk's CagriSema trial showed disappointing weight loss results, leaving room for Lilly to maintain dominance in the obesity treatment market with its competing therapies.

STOXX 600 inches lower at start of Christmas week; Novo Nordisk surges

European markets see mixed trends as Novo Nordisk's share surge offsets losses in travel and leisure sectors amid economic concerns and ECB predictions influencing investor sentiment.

Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea

The FDA approved Eli Lilly's Zepbound for treating obstructive sleep apnea in obese adults, marking a significant advancement in addressing this widespread disorder and expanding market potential.

Investing.com’s stocks of the week

This week, Micron and Novo Nordisk faced declines due to disappointing earnings and trial results, while MicroStrategy and Coinbase stock performance fluctuated alongside Bitcoin's price changes.

FedEx, Eli Lilly, Occidental rise premarket; Nike, Novo Nordisk fall

Viking Therapeutics stock surges 12% amid Novo Nordisk trial woes

Novo slumps, Lilly gains on trial data results

Novo Nordisk's shares fell 19% after phase 3 trial results for CagriSema, an obesity drug, disappointed. Eli Lilly's stock rose amid growing confidence in its obesity treatments.

In weight loss battle, Novo and Lilly face growing offensive from licensed copies

Novo Nordisk and Eli Lilly face competition from cheaper drug copies abroad, threatening their market share and prompting potential price declines amid rising global obesity rates.

Novo Holdings completes $16.5 billion takeover of Catalent

Novo Holdings has acquired Catalent for $16.5 billion, enhancing production capabilities for the popular weight-loss drug Wegovy amid concerns from consumer groups and unions.

EU to review studies linking Novo Nordisk's Ozempic to rare eye condition

The EMA is reviewing studies linking Novo Nordisk's Ozempic diabetes drug to a rare eye condition, although no direct cause-and-effect relationship has been established yet.